NEW YORK, November 1, 2022 /PRNewswire/ — According to the latest market research study released by P&S Intelligence, the BPH Treatment Market billed $11,892.8 million Sales in 2021 that will touch $18,837.7 million by 2030, with a CAGR of 5.2% from 2021 to 2030. This is due to rising cases of BPH, rising preference for minimally invasive surgeries, and leaps in investment in research into novel treatments.
According to Medscape, approximately 50% of men by the age of 60 will develop histopathological BPH. By the age of 85, this percentage increases to 90%.
One way in which BPH management has benefited significantly from advanced technology is the adoption of procedures that do not require general anesthesia or lengthy hospital stays. The prostate can now be fitted with a state-of-the-art mechanical implant that moves the penetrating lobes into a better position to improve urine flow.
Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-treatment-bph-market/report-sample
Minimally invasive procedures are widely accepted
Surgery is a superior option to treating BPH with medication. However, due to the postoperative damage that surgical cuts and burns can cause, patients tend to opt for medication. Recently, patient perception has changed with the development of minimally invasive techniques, giving surgical equipment manufacturers a competitive advantage.
Patient demand for alpha-blockers is increasing
In 2021, around 85% of the market share was acquired for drug treatment. This is due to the increasing demand for alpha-blockers, which help facilitate urinary flow by relaxing the bladder neck muscles and prostate.
Home health care hiring brings in more revenue
Home health care facilities hold the larger market share and will see a CAGR of over 5% in the coming years. This is due to the increasing number of patients being prescribed…
